Euretina 2026
Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, Casey Eye Institute, School of Medicine
Title: Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations